Erste Group Bank Has Bullish Outlook for BMY FY2026 Earnings

Key Points

• Erste Group Bank raised its FY2026 EPS estimate for Bristol Myers Squibb to $6.31 from $6.28, slightly above the consensus estimate of $6.30.
• Bristol Myers Squibb reported better-than-expected Q1 results, with EPS of $1.58 versus $1.42 expected and revenue of $11.49 billion versus $10.93 billion expected.
• The company maintained its FY2026 guidance4.5% dividend yield.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Analysts at Erste Group Bank increased their FY2026 earnings per share estimates for Bristol Myers Squibb in a research note issued to investors on Tuesday, May 5th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings of $6.31 per share for the year, up from their previous estimate of $6.28. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.30 per share.

A number of other brokerages also recently commented on BMY. Bank of America decreased their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a report on Thursday, April 9th. Weiss Ratings restated a "hold (c)" rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Citigroup reiterated a "neutral" rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Wells Fargo & Company reiterated an "outperform" rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $56.10 on Monday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The company has a market cap of $114.56 billion, a PE ratio of 15.76, a P/E/G ratio of 0.16 and a beta of 0.26. The business has a 50 day moving average of $59.28 and a 200 day moving average of $54.91. Bristol Myers Squibb has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. Bristol Myers Squibb's dividend payout ratio is 70.79%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.05% of the company's stock.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors have recently modified their holdings of BMY. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter valued at $25,000. Physician Wealth Advisors Inc. boosted its position in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 202 shares during the last quarter. Bayban purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.